{"filings":[{"id":94298,"accession_number":"0001178913-26-002455","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $3.5M; cash $20.4M; EB613 Phase 3 protocol submitted to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.5M ($0.07/share) vs $2.6M in Q1 2025; R&D expenses rose to $2.3M from $1.1M.","Cash $20.4M as of May 8, 2026, including BVF private placement proceeds; runway into Q1 2027.","EB613 Phase 3 protocol submitted to FDA; bridging study completed for single-tablet formulation.","EB612 hypoparathyroidism program prioritized with OPKO; IND expected late 2026.","Geno Germano appointed Chairman in February; Steve Rubin joined Board."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94297,"accession_number":"0001178913-26-002001","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Entera Bio raises $10M in private placement with BVF Partners to fund phase 3 osteoporosis study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10.0M from sale of 7,827,789 units at $1.2775/unit to funds affiliated with BVF Partners LP.","Each unit consists of one ordinary share (or pre-funded warrant) and one warrant to purchase 1.5 ordinary shares at $1.24/share.","Warrants become exercisable 6 months after closing (April 2, 2026) and expire in 5 years; cash exercise could bring additional ~$14.5M.","Net proceeds intended to support initiation of phase 3 registrational study of EB613 for postmenopausal osteoporosis and for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106542,"accession_number":"0001178913-26-001792","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio FY2025 net loss $11.4M, cash runway to mid-Q3 2026; EB613 Phase 3 submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.4M ($0.25/sh) vs $9.5M in FY2024; R&D expenses $6.0M up from $4.5M.","Cash $14.9M at Dec 31, 2025 incl. $7.8M restricted for OPKO collab; operating cash burn $7.4M.","EB613 Phase 3 protocol submitted Mar 2026; FDA feedback expected late Apr 2026 with topline in H2 2028.","EB612 (LA-PTH) collaboration with OPKO expanded; IND filing expected late 2026.","EB618 (oral OXM) PK/PD validation complete; Phase 1 initiation dependent on injectable data by YE 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106541,"accession_number":"0001178913-26-000714","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Entera Bio submits streamlined Phase 3 protocol for EB613 to FDA; topline data H2 2028","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 3 trial to enroll 750 postmenopausal women with osteoporosis; primary endpoint total hip BMD at 12 months.","Single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet candidate; no bridging needed.","FDA feedback expected within 60 days; topline results anticipated in second half of 2028, one year earlier than prior guidance.","12-month open-label extension study submitted; will run in parallel with potential NDA review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106540,"accession_number":"0001178913-26-000355","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Entera Bio appoints former Pfizer exec Geno J. Germano as Chairman, replacing Gerald Lieberman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geno Germano appointed Class III director and Chairman of the Board effective February 4, 2026.","Gerald Lieberman resigned as Chairman and Director effective Feb 4, 2026, no disagreement.","Germano led Pfizer's $14B Global Innovative Pharma business as Group President until 2016.","Entera plans Phase 3 registrational study for EB613 (osteoporosis) and first-in-human for Long-Acting Oral PTH (hypoparathyroidism) in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106539,"accession_number":"0001178913-26-000300","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Entera Bio expands OPKO pact to include oral LA-PTH; appoints OPKO exec Rubin to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded collaboration covers once-daily oral LA-PTH tablet for hypoparathyroidism; 50/50 cost sharing.","IND filing for LA-PTH expected late 2026 after positive PK/PD data in December 2025.","Gerry Ostrov resigned as director effective Feb 1, 2026; Steven Rubin appointed as Class III director.","Rubin also chairs audit committee and serves on compensation committee; he is EVP at OPKO.","Oral OXM program progressing; Phase 1 injectable OXM data expected late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122880,"accession_number":"0001178913-25-003851","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports Q3 net loss $3.2M; FDA agrees BMD endpoint for EB613 Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($0.07/share) vs $3.0M ($0.08/share) in Q3 2024; cash $16.6M through mid-Q3 2026.","FDA agreed BMD as primary endpoint for single Phase 3 trial of EB613 (oral PTH) for osteoporosis; supports NDA.","EB613 Phase 2 data showed significant BMD gains in younger postmenopausal women, presented at NAMS and ASBMR.","Next-gen EB613 Phase 1 trial on track for late 2025; GLP-2 and OXM programs with OPKO advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":42000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139580,"accession_number":"0001178913-25-002701","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q2 net loss $2.7M; FDA agrees on EB613 Phase 3 design with BMD endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA provided written concurrence on Phase 3 study for EB613, using total hip BMD as primary endpoint for NDA via 505(b)(2) pathway.","FDA waived dedicated oral carcinogenicity and DART studies for EB613, reducing regulatory burden.","Next-generation EB613 enters Phase 1 in November 2025; OPKO collaboration GLP-1/glucagon candidate OPK-88006 IND expected H1 2026.","Cash $18.9M including $8M restricted for OPKO; runway through mid-Q3 2026.","Q2 net loss $2.7M ($0.06 per share) vs $2.1M ($0.06 per share) a year ago; R&D up to $1.5M from $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":42000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139579,"accession_number":"0001178913-25-002484","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entera Bio wins FDA agreement to use BMD as primary endpoint for EB613 Phase 3 osteoporosis study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed single 24-month, placebo-controlled Phase 3 study with total hip BMD as primary endpoint; fracture incidence as key secondary.","Shift from traditional fracture-endpoint trials; no dedicated oral carcinogenicity or DART studies required by FDA.","Phase 3 study targets postmenopausal women; EB613 is first oral anabolic tablet for osteoporosis.","FDA's SABRE qualification still expected later this year but not needed to proceed.","CEO Miranda Toledano calls it a major milestone; no new osteoporosis drug approved by FDA since 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139578,"accession_number":"0001178913-25-002406","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio shareholders elect Haya Taitel to board; approve executive compensation amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Haya Taitel elected as director for three-year term with 17,288,920 votes for, 3,069,140 against.","Revised compensation terms for CEO Miranda Toledano approved (19,524,783 for, 428,993 against).","Shareholders ratified Kesselman & Kesselman (PwC) as auditors for FY2025 with 26,617,578 votes for.","All seven proposals passed, including advisory say-on-pay and compensation policy amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157153,"accession_number":"0001178913-25-001673","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $2.6M ($0.06/sh); cash runway to mid-Q3 2026; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M ($0.06 per share) for Q1 2025 vs $2.0M ($0.05) in Q1 2024; operating expenses $2.6M.","Cash and equivalents $20.6M as of Mar 31, 2025; expects to fund operations through mid-Q3 2026.","EB613 (oral PTH) bone data presented at WCO-IOF-ESCEO Apr 2025; Next Gen EB613 Phase 1 planned H2 2025.","Collaboration with OPKO for oral GLP-1/Glucagon program; IND filing planned late 2025/early 2026.","Appointed Cherin Smith as EVP Clinical Ops (Mar) and Leslie Gautam as CBO (May 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":42000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175509,"accession_number":"0001178913-25-001110","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports FY2024 net loss of $9.5M; cash $21M as of March 28, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.5M ($0.25 per share) vs $8.9M ($0.31 per share) in FY2023.","Cash and equivalents $8.7M at Dec 31, 2024; $21M as of March 28, 2025 after new investments.","R&D expenses flat at $4.5M; G&A increased to $5.1M from $4.4M.","Entera and OPKO entered oral GLP-1/Glucagon license agreement; IND filing expected in 2025.","EB613 Phase 3 study planned pending FDA surrogate endpoint qualification; SABRE ruling awaited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175508,"accession_number":"0001178913-25-000857","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Entera Bio-OPKO collaboration: oral GLP-1/glucagon tablet, $8M equity investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OPKO purchased 3,685,226 Entera shares at ~$2.17/share ($8M) to fund Entera's 40% development cost share through Phase 1.","Profit/cost split initially 60% OPKO / 40% Entera; opt-out after Phase 1 yields 85%/15% with OPKO funding.","Parties expect to file IND with FDA later in 2025 for oral tablet combining OPK-88006 and Entera's N-Tab™ technology.","OPKO subject to 12-month lockup on shares and 24-month standstill on acquiring additional Entera equity.","Preclinical data reported September 2024 showed favorable pharmacodynamic and pharmacokinetic profiles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175507,"accession_number":"0001178913-25-000080","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Entera Bio files legal opinion exhibit, no material business update","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing solely to submit Exhibit 5.1 (legal opinion of Herzog Fox & Neeman) and Exhibit 23.1 (consent).","No financial results, operational milestones, or guidance changes reported.","The warrant exercise price of $5.85 per ordinary share is unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192458,"accession_number":"0001178913-24-004020","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K/A","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio Board sets annual say-on-pay votes after shareholder vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders at July 31, 2024 annual meeting voted on frequency of advisory votes on executive compensation.","Frequency of one year received the highest number of votes cast.","Board determined to hold a non-binding advisory vote on executive compensation every year until further decision.","This 8-K/A amends the original 8-K filed August 2, 2024 to disclose the Board's frequency determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192459,"accession_number":"0001178913-24-003556","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q3 net loss $3.0M ($0.08/shr); cash $6.9M; awaits FDA SABRE ruling Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.0M ($0.08 basic/diluted EPS) for Q3 2024 vs $2.4M ($0.08) in Q3 2023; operating expenses $3.0M vs $2.4M.","Cash and equivalents $6.9M; expects runway into Q3 2025.","EB613 (oral PTH) phase 3 prep ongoing; FDA decision on SABRE regulatory endpoint expected January 2025.","Oral GLP-1/glucagon (with OPKO) showed favorable PK/PD; plans to present at clinical conference.","Oral GLP-2 tablet for short bowel syndrome; final PK/PD data expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":99000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208929,"accession_number":"0001178913-24-002520","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q2 2024 net loss $2.1M; cash runway into Q3 2025; EB613 milestone expected","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M ($0.06 per share) vs $2.3M ($0.08) in Q2 2023; cash $9.1M at June 30, 2024.","R&D expenses $1.1M (down $0.1M YoY); G&A flat at $1.1M; operating expenses $2.2M.","EB613 (oral PTH) Phase 2 data published in JBMR; FDA SABRE endpoint ruling expected ~5 months.","EB612 hypoparathyroidism Phase 1 data at ENDO 2024; potential move to Phase 2 soon.","Collaboration with OPKO on oral GLP-2 (short bowel) and GLP-1/glucagon (obesity) ongoing; PK data due H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":57000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208928,"accession_number":"0001178913-24-002393","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio shareholders approve all 8 proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Miranda Toledano and Yonatan Malca to three-year board terms with ~99% of votes cast.","Approved one-time CEO compensation grant for Miranda Toledano (14,365,894 for, 544,357 against).","Approved amendment to 2018 Equity Incentive Plan, increasing shares by 1,788,515 (14,131,640 for).","Ratified Kesselman & Kesselman (PwC) as independent auditors for FY2024 with overwhelming support.","Advisory vote on executive compensation passed; the most frequent frequency vote was 'one year'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226748,"accession_number":"0001178913-24-001681","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $2.0M; cash $9.2M; FDA catalyst path for EB613","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $2.0M ($0.05 per share) vs $2.2M ($0.08) in Q1 2023.","Cash $9.2M at March 31, 2024; runway into Q3 2025.","R&D expenses $0.7M (down from $0.9M); G&A flat at $1.3M.","FDA to rule on BMD as surrogate for fractures within 10 months – key catalyst for EB613 Phase 3.","Oral GLP-2 tablets showed 10-fold higher plasma exposure vs teduglutide; OXM PK data expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}